Anti-arthritic effects demonstrated by an interleukin-2 receptor-targeted cytotoxin (DAB486IL-2) in rat adjuvant arthritis.
DAB486IL-2 is an interleukin-2 receptor-specific cytotoxin which selectively targets and kills cells which bear the high-affinity form of the IL-2 receptor. Since elimination of activated T lymphocytes may be useful in the treatment of rheumatoid arthritis, the effect of DAB486IL-2 treatment in an animal model of arthritis was investigated. We demonstrated that rats treated with DAB486IL-2 during the induction phase of disease have delayed onset of symptoms and significantly reduced severity of inflammation as well as a depressed proliferative response to mycobacterial stimulation in vitro. In addition, the presence of preexisting antibodies to the molecule had no impact on the anti-arthritic effects observed in this model. These data suggest that DAB486IL-2 may have therapeutic potential in the treatment of rheumatoid arthritis.
Bacha
P
P
Seragen, Inc., Hopkinton, MA 01748.
Forte
S E
SE
Perper
S J
SJ
Trentham
D E
DE
Nichols
J C
JC
D000818:Animals; D001169:Arthritis, Experimental / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D004167:Diphtheria Toxin / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D007376:Interleukin-2 / Q000276:immunology / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects; D011859:Radiography; D051381:Rats; D011917:Rats, Inbred Lew; D015375:Receptors, Interleukin-2 / Q000187:drug effects* / Q000502:physiology; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D013997:Time Factors
C054780:DAB(486)-interleukin 2; D004167:Diphtheria Toxin; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins